Bio Green Med Solution, Inc. — Director's Dealing 2023

Feb 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2023-01-31

Reporting Person: Rombotis Spiro George (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-31	Common Stock	A	57600	—	Acquired	62588	Direct

Footnotes

F1: The reporting person received an award of 57,600 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.

F2: Includes 4,988 shares of common stock and 57,600 restricted stock units.